Discontinuation rates of cholesterol-lowering medications: Implications for primary care

American Journal of Managed Care

Volumn 5, Issue 4, 1999, Pages 437-444

  Hiatt, Janet G ^a,b   Shamsie, Stephanie G ^a   Schectman, Gordon ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA Outpatient Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; STATIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DRUG TOLERABILITY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HYPERLIPIDEMIA; LONG TERM CARE; MALE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; EVALUATION STUDIES; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; VETERANS; WISCONSIN;

EID: 0032937750     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
3. Sempos C, Cleeman J, Carroll M, et al. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-3014.
4. Heudebert G, Ruiswyk JV, Hiatt J, et al. Combination drug therapy for hypercholesterolemia: The trade-off between cost and simplicity. Arch Intern Med 1993;153:1828-1837.
5. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
6. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol 1993;71:759-765.
7. Simons L, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208-211.
8. Andrade S, Walker A, Gottlieb L, et al. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
9. Adult Treatment Panel II. Detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1329-1456.
10. Superko H, Greenland P, Manchester R, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992;70:135-140.
11. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve compliance to niacin or bile acid sequestrants. Ann Pharmacother 1994;28:29-34.
12. Thompson G, Maher V, Matthews S, et al. Familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-816.
13. Schectman G, Wolff N, Byrd J, et al. Physician extenders for cost-effective hypercholesterolemia management. J Gen Intern Med 1996;11:277-286.
14. Gibbons L, Gonzalez V, Gordon N, et al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-385.
15. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment. Ann Intern Med 1996;125:990-1000.
16. McKenney J, Proctor J, Harris S, et al. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677.
17. Morgan J, Capuzzi D, Guyton J, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1996;1:195-202.
18. Insull W, Marquis N, Tsianco M. Comparison of the efficacy of Questran light, a new formulation of cholestyramine powder, to regular Questran in maintaining lowered plasma cholesterol levels. Am J Cardiol 1991;67:501-505.
19. Linet O, Grzegorczyk C, Demke D. The effect of encapsulated, low-dose colestipol in patients with hyperlipidemia. J Clin Pharmacol 1988;28:804-806.